Expert Insights: 19th International Ultmann Chicago Lymphoma Symposium
Release Date: June 15, 2022
Expiration Date: June 15, 2023
This activity has been designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.
After completing this activity, the participant should be better able to:
- Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma
- Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma
- Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data
- Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL
- Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma
ACCREDITATION AND CREDIT DESIGNATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professions Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content. The staff of the Center for Continuing Medical Education, Bio Ascend, and Meeting Achievements have disclosed that they have no relevant financial relationships with ACCME defined commercial interests.
Sonali M. Smith, MD, FASCO
Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Sonali Smith, MD, FASCO served as a consultant for Gamida Cell, Gilead, Bristol Meyers Squibb, Adaptive, ADC Therapeutics, Morphosys, Janssen, Karyopharm, and Bantam and as a speaker for ADC Therapeutics and Karyopharm. Dr. Smith served as a consultant for Genentech, TGTX, and Celgene. She has received research funding from Celgene, TGTX, Genetech, and Bristol Meyers Squibb. Dr. Smith will discuss the investigational/unapproved use of approved agents in unapproved settings or unapproved agents in development. She will disclose when this is the case.
Andrew Evens, DO, MSC, FACP
Associate Director for Clinical Services, Rutgers Cancer Institute,
System Director of Medical Oncology and Oncology Lead for Combined Medical Group
New Brunswick, New Jersey
Andrew Evens, DO, MSc, FACP serves as a researcher and on the educational advisory board for Seattle Genetics, Abbvie, MorphoSys, Epizyme, Pharmacyclics, and Novartis, serves on the educational advisory board for Research to Practice, Cota, Curio, Hutchmed, OncLive, and Patient Power, and serves on the Research Advisory Board for Incyte, and Karyopharm. Dr. Evens will discuss the unapproved/investigational use regarding checkpoint inhibitors in lymphoma.
Timothy Fenske, MD, MS
Professor, Division of Hematology and Oncology
Medical College of Wisconsin
Timothy Fenske, MD, MS serves as a consultant and speaker for Adaptive Biotech, AstraZeneca, Bristol Meyers Squibb, MorphoSys, Seattle Genetics, and TG Therapeutics. He serves as a speaker for ADC Therapeutics and Kite Sanofi and as a consultant for Pharmacyclics/ AbbVie, Beigene and Biogen. He served as a consultant for CSL Therapeutics, Karyopharm, and Kyowa, as a speaker for Veristem, and as a consultant and speaker for Servier Pharmaceuticals.
The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.
This activity is supported by educational grants from AbbVie, Inc., AstraZeneca Pharmaceuticals, Genentech, Inc., Genmab, Jannsen Scientific Affairs, LLC, MorphoSys, Novartis Corporation, and Seagen.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.